PAM
REGN icon

Palisade Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Palisade Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$563 – 558
2025
Q3 		$563 Buy
+1
New +$565 ﹤0.01% 553

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Palisade Asset Management's REGN Position: Q4 2025 in Review

Palisade Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 1 share — an estimated $563 sold.

Palisade Asset Management first reported a position in REGN in Q3 2025 and held it in 1 quarter. The position peaked at $563 in Q3 2025. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Palisade Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Palisade Asset Management sold 1 Regeneron Pharmaceuticals share in Q4 2025, an estimated $563.
  • Palisade Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Palisade Asset Management's Regeneron Pharmaceuticals position peaked at $563 in Q3 2025.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Palisade Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.